Pune-based Gennova Biopharmaceuticals is developing India’s first homegrown mRNA vaccine that will start trials on humans in February.

Gennova submitted the phase 2 trial data to the Drugs Controller General of India (DCGI), and its Subject Expert Committee (SEC) is expected to review the data this week, official sources told news agency ANI.

According to news agency Reuters, the vaccine was found to be “safe, tolerable, and immunogenic” in the participants of an initial study.

Meanwhile, Gennova also developed an Omicron-specific vaccine that was developed using the same mRNA technology. On condition of anonymity, sources told Reuters that the vaccine might need a small trial in India before being rolled out as a booster dose or standalone vaccine.

Read more at https://news.abplive.com/health/gennova-biopharmaceuticals-develops...